- Home
- SMTC vs TGTX Comparison
SMTC vs TGTX Comparison
Compare SMTC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTC
- TGTX
- Stock Information
- Founded
- SMTC 1960
- TGTX 1993
- Country
- SMTC United States
- TGTX United States
- Employees
- SMTC N/A
- TGTX N/A
- Industry
- SMTC Semiconductors
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- SMTC Technology
- TGTX Health Care
- Exchange
- SMTC Nasdaq
- TGTX Nasdaq
- Market Cap
- SMTC 4.3B
- TGTX 4.2B
- IPO Year
- SMTC N/A
- TGTX 1995
- Fundamental
- Price
- SMTC $62.22
- TGTX $32.04
- Analyst Decision
- SMTC Strong Buy
- TGTX Strong Buy
- Analyst Count
- SMTC 13
- TGTX 5
- Target Price
- SMTC $60.54
- TGTX $45.00
- AVG Volume (30 Days)
- SMTC 2.0M
- TGTX 2.1M
- Earning Date
- SMTC 08-25-2025
- TGTX 11-03-2025
- Dividend Yield
- SMTC N/A
- TGTX N/A
- EPS Growth
- SMTC N/A
- TGTX N/A
- EPS
- SMTC 0.29
- TGTX 0.36
- Revenue
- SMTC $996,476,000.00
- TGTX $454,069,000.00
- Revenue This Year
- SMTC $15.91
- TGTX $82.58
- Revenue Next Year
- SMTC $9.30
- TGTX $44.99
- P/E Ratio
- SMTC $217.16
- TGTX $88.81
- Revenue Growth
- SMTC 22.22
- TGTX 30.96
- 52 Week Low
- SMTC $24.05
- TGTX $21.16
- 52 Week High
- SMTC $79.52
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- SMTC 66.56
- TGTX 56.50
- Support Level
- SMTC $59.71
- TGTX $31.29
- Resistance Level
- SMTC $63.25
- TGTX $32.56
- Average True Range (ATR)
- SMTC 2.20
- TGTX 1.15
- MACD
- SMTC 0.12
- TGTX 0.32
- Stochastic Oscillator
- SMTC 85.64
- TGTX 73.48
About SMTC Semtech Corporation
Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems and IoT Connected Services. The majority of the company's revenue is earned through Analog Mixed Signal and Wireless segment. Geographically majority of the company's revenue is earned from Asia Pacific region, company also operates in North America and Europe.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.